Current Report Filing (8-k)
July 18 2022 - 6:57AM
Edgar (US Regulatory)
0000827871
false
0000827871
2022-07-18
2022-07-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): July 18, 2022
Eagle Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
001-36306 |
20-8179278 |
(State
or other jurisdiction of |
(Commission File Number) |
(IRS Employer Identification No.) |
incorporation) |
|
|
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 326-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name
of each exchange on which registered |
Common Stock (par value $0.001 per share) |
|
EGRX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On July 18, 2022, Eagle Pharmaceuticals, Inc.,
or the Company, issued a press release announcing the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial.
A copy of the full text of the press release
referenced above is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Safe Harbor for Forward-Looking Statements
This Current Report on Form 8-K contains
forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities
laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,”
“will,” “would,” “could,” “should,” “may,” “remain,” “potential,”
“prepare,” “expected,” “believe,” “plan,” “near future,” “belief,”
“guidance,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements
include, but are not limited to, statements regarding future events such as: statements concerning the potential approval of the Company’s
product candidates and the potential launch of landiolol, if approved; the potential annual sales of BARHEMSYS and BYFAVO; the ability
of the Company’s and its employees to execute on the Company’s strategy and capture the value of hospital-based products;
expectations with respect to synergies; expectations regarding the Company’s future growth; and the ability of the Company’s
product candidates to deliver value to stockholders. All of such statements are subject to certain risks and uncertainties, many of which
are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those
expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are
not limited to: the risk that the anticipated benefits of the Company’s recently completed transaction with Acacia Pharma are not
realized; the impacts of the COVID-19 pandemic and geopolitical events such as the conflict in Ukraine, including disruption or impact
in the sales of the Company’s marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory
review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company’s
third party partners and disruption of the global economy, and the overall impact of the COVID-19 pandemic or other events on the Company’s
business, financial condition and results of operations; whether the Company will incur unforeseen expenses or liabilities or other market
factors; whether the Company will successfully implement its development plan for its product candidates; delay in or failure to obtain
regulatory approval of the Company’s or its partners’ product candidates; whether the Company can successfully market and
commercialize its products or product candidates; the success of the Company’s relationships with its partners; the availability
and pricing of third party sourced products and materials; the outcome of litigation involving any of its products or that may have an
impact on any of the Company’s products; successful compliance with the FDA and other governmental regulations applicable to product
approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects
of public health issues, including the COVID-19 pandemic and geopolitical events, on economic activity and the performance of the financial
markets generally; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties;
competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market;
the risks inherent in the early stages of drug development and in conducting clinical trials; and factors in addition to the foregoing
that may impact the Company’s financial projects and guidance, including among other things, any potential business development
transactions, acquisitions, restructurings or legal settlements, in addition to any unanticipated factors, that may cause the Company’s
actual results and outcomes to materially differ from its projections and guidance; and those risks and uncertainties identified in the
“Risk Factors” sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed
with the Securities and Exchange Commission (the “SEC”) on March 8, 2022 and its other subsequent filings with the SEC,
including the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which the Company filed with
the SEC on May 9, 2022. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking
statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required
by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after
the date on which they were made.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 18, 2022 |
EAGLE PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Scott Tarriff |
|
|
Scott Tarriff |
|
|
Chief Executive Officer |
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024